Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prostatic artery embolization in men with severe hemophilia a: a case report of two patients

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{f942da5946344238ba5d1ea33df5ee25,
title = "Prostatic artery embolization in men with severe hemophilia a: a case report of two patients",
abstract = "BACKGROUND: This is the first case report describing the peri- and postoperative hemostasis plans in two men with severe hemophilia A (HA) who underwent prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH).CASE PRESENTATION: Two patients with severe HA and lower urinary tract symptoms (LUTS) not responding to medical therapy underwent PAE at our institution. In both patients, intermittent administration of decreasing doses of extended half-life recombinant factor VIII (EHL rFVIII) concentrate from 30 min before to 7 days after the PAE resulted in good hemostatic control. In addition to EHL rFVIII, tranexamic acid was administered in the same timeframe to augment the action of EHL rFVIII and to account for possible mucosal bleeding from the urinary tract. Both patients reported a minor localized hematoma at the femoral puncture site in the right groin, that resolved spontaneously. No other bleeding complications were observed.CONCLUSIONS: The procoagulant effects of the chosen dosing of EHL rFVIII showed sufficient to perform a technically successful embolization. At 6 months follow-up, both patients had significant reduction in self-reported urinary symptoms and were content with the outcome.",
author = "Petra Svarc and Peter Kampmann and Lars L{\"o}nn and R{\o}der, {Martin Andreas}",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = apr,
day = "21",
doi = "10.1186/s42155-022-00299-x",
language = "English",
volume = "5",
pages = "21",
journal = "CVIR endovascular",
issn = "2520-8934",
publisher = "SpringerOpen",
number = "1",

}

RIS

TY - JOUR

T1 - Prostatic artery embolization in men with severe hemophilia a

T2 - a case report of two patients

AU - Svarc, Petra

AU - Kampmann, Peter

AU - Lönn, Lars

AU - Røder, Martin Andreas

N1 - © 2022. The Author(s).

PY - 2022/4/21

Y1 - 2022/4/21

N2 - BACKGROUND: This is the first case report describing the peri- and postoperative hemostasis plans in two men with severe hemophilia A (HA) who underwent prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH).CASE PRESENTATION: Two patients with severe HA and lower urinary tract symptoms (LUTS) not responding to medical therapy underwent PAE at our institution. In both patients, intermittent administration of decreasing doses of extended half-life recombinant factor VIII (EHL rFVIII) concentrate from 30 min before to 7 days after the PAE resulted in good hemostatic control. In addition to EHL rFVIII, tranexamic acid was administered in the same timeframe to augment the action of EHL rFVIII and to account for possible mucosal bleeding from the urinary tract. Both patients reported a minor localized hematoma at the femoral puncture site in the right groin, that resolved spontaneously. No other bleeding complications were observed.CONCLUSIONS: The procoagulant effects of the chosen dosing of EHL rFVIII showed sufficient to perform a technically successful embolization. At 6 months follow-up, both patients had significant reduction in self-reported urinary symptoms and were content with the outcome.

AB - BACKGROUND: This is the first case report describing the peri- and postoperative hemostasis plans in two men with severe hemophilia A (HA) who underwent prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH).CASE PRESENTATION: Two patients with severe HA and lower urinary tract symptoms (LUTS) not responding to medical therapy underwent PAE at our institution. In both patients, intermittent administration of decreasing doses of extended half-life recombinant factor VIII (EHL rFVIII) concentrate from 30 min before to 7 days after the PAE resulted in good hemostatic control. In addition to EHL rFVIII, tranexamic acid was administered in the same timeframe to augment the action of EHL rFVIII and to account for possible mucosal bleeding from the urinary tract. Both patients reported a minor localized hematoma at the femoral puncture site in the right groin, that resolved spontaneously. No other bleeding complications were observed.CONCLUSIONS: The procoagulant effects of the chosen dosing of EHL rFVIII showed sufficient to perform a technically successful embolization. At 6 months follow-up, both patients had significant reduction in self-reported urinary symptoms and were content with the outcome.

UR - http://www.scopus.com/inward/record.url?scp=85128607600&partnerID=8YFLogxK

U2 - 10.1186/s42155-022-00299-x

DO - 10.1186/s42155-022-00299-x

M3 - Journal article

C2 - 35449378

VL - 5

SP - 21

JO - CVIR endovascular

JF - CVIR endovascular

SN - 2520-8934

IS - 1

M1 - 21

ER -

ID: 78362426